Cigna Group (CI)
(Delayed Data from NYSE)
$358.58 USD
+9.74 (2.79%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $358.57 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$358.58 USD
+9.74 (2.79%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $358.57 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
5 Top-Ranked Insurance Stocks to Buy for 2018
by Zacks Equity Research
As we ring New Year, here's a list of five Top-Ranked Insurance Stocks for 2018 to make investment portfolio a compelling one for maximizing returns.
Top Ranked Growth Stocks to Buy for December 28th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 28th:
Here's Why You Should Hold Onto Cboe Global Markets Stock
by Zacks Equity Research
Cboe Global Markets (CBOE) remains well poised for growth on the back of its strong market position and a global reach with potent proprietary products.
UnitedHealth (UNH) Arm to Buy Chilean Company for $2.8B
by Zacks Equity Research
UnitedHealth (UNH) is set to buy Empresas Banmedica in order to expand its international operations.
Old Republic Issues Q4 Estimates, Okays Special Dividend
by Zacks Equity Research
Old Republic (ORI) estimates net realized investment gains of $150 million as well as to incur $45 million of additional expense in Q4. The company also approves a special dividend of $1.00 per share.
Is Cigna Corporation (CI) a Good Stock for Value Investors?
by Zacks Equity Research
Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Zacks Analyst Blog Highlights: Wal-Mart, Procter & Gamble, NVIDIA, Cigna and McKesson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wal-Mart, Procter & Gamble, NVIDIA, Cigna and McKesson
Anthem Buys HealthSun to Expand Medicare Business in Florida
by Zacks Equity Research
Anthem's (ANTM) buyout of HealthSun reflects its long-term strategy to grow in the Medicare Advantage business.
Cigna (CI) Buys Brighter to Enhance Technology Investment
by Zacks Equity Research
Cigna's (CI) buyout of Brighter reflects its consistent efforts to scale up technological innovation.
Pick 4 Solid Insurance Stocks From the Bull Market in 2017
by Zacks Equity Research
We zero in on four best insurance bets so far this year to invest in and reap benefits from.
Anthem's (ANTM) Notes Receive Rating Action From A.M Best
by Zacks Equity Research
Anthem (ANTM) receives favorable ratings from the rating agencies on the back of operational excellence and financial flexibility
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
by Zacks Equity Research
Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.
Cigna (CI) Q3 Earnings Beat on Higher Enrollment, Guides Up
by Zacks Equity Research
Cigna's (CI) strong third-quarter earnings were driven by broad-based growth across its business segments.
Cigna Corp.'s (CI) Q3 Earnings and Revenues Beat, Guides Up
by Zacks Equity Research
Cigna's (CI) strong third-quarter earnings were driven by broad based growth across its business segments.
Will Higher Membership, Revenues Aid Cigna (CI) Q3 Earnings?
by Zacks Equity Research
Cigna (CI) is likely to perform well in Q3 on the back of membership growth, higher contribution from its segments and disciplined capital management.
Will Increased Visits Drive Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) earnings will benefit from its premier consumer engagement capabilities, broad network and scalable platform, which will increase visits and clients.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
UnitedHealth (UNH) Q3 Earnings Likely to Beat: Here's Why?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter earnings are expected to benefit from strong contribution from both its segments along earnings accretion from disciplined capital management.
Markel (MKL) Issues Life Sciences Coverage in Primary Market
by Zacks Equity Research
Markel's (MKL) introduction of biomedical and life sciences coverage in the US primary insurance segment supports its strategic plan to grow organically.
Why You Should Offload Travelers (TRV) From Your Portfolio
by Zacks Equity Research
Catastrophe losses and lower investment income pose a threat to Travelers' (TRV) operational performance.
W.R. Berkley's Exposure to Cat Losses Continues to Bother
by Zacks Equity Research
W.R. Berkley's (WRB) exposure to cat losses, declining gross premiums trend as well as a continued weak performance at the global reinsurance segment raise concerns.
Prudential Financial's Organic Growth Counts, High Costs Ail
by Zacks Equity Research
Prudential Financial's (PRU) sustained operational performance and a solid capital back-up make it an investment-worthy stock. However, rising expenses remain a concern.
Why the Earnings Streak Will Continue for Cigna (CI)
by Zacks Equity Research
Cigna (CI) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.
4 HMOS for Gains Amid Constant Regulatory Chaos
by Zacks Equity Research
Despite the continuing chaos and insecurity storming the health care space with respect to repeal and replace of the old order, these healthcare stocks look solid bets to put money on.
Chubb (CB) and Subsidiaries' Ratings Reiterated by A.M. Best
by Zacks Equity Research
Chubb (CB) and units' rating actions received from A.M. Best might help the property and casualty insurer retain investors' faith and write more businesses in the short term.